Parkinson's Disease news breaks that a drug that could stop or slow Parkinson’s disease (PD) is advancing in clinical testing.
, the drug isradipine is proceeding to Phase III testing, the last step before regulatory approval. With a $23 million grant from the National Institutes of Health, researchers will test if isradipine has an effect on PD progression. Previous studies showed drugs in the same class, calcium channel blockers, were associated with lower incidence of PD.
When recruitment for this study begins later this year, it will be the most advanced, current trial of a disease-modifying therapy for PD.